#USA #New York #Neurology #Holmusk #NeuroBlu

Holmusk Expands NeuroBlu to 46 Million Patients

In a groundbreaking move for healthcare data, Holmusk has announced the remarkable expansion of its NeuroBlu platform, now covering over 46 million de-identified patient lives derived from longitudinal electronic health record (EHR) data. This notable growth, which adds more than five million patients to the platform, is particularly significant as it aims to enhance research capabilities in neurology and behavioral health.

Major Contributions to Neurological Health

Holmusk's expansion is strongly anchored by the addition of two leading neurological health systems recognized by the U.S. News & World Report: one top-ranked health system from the Northeast, which excels in both inpatient and outpatient neurology, and another in the Southeast with a robust neurological program. Together, these institutions help strengthen NeuroBlu’s geographic and clinical coverage, which now spans community clinics, specialized neurology programs, and academic medical centers across the United States.

According to Nawal Roy, CEO and Founder of Holmusk, “The convergence of neurological and behavioral health diagnoses within a singular longitudinal record is not merely a feature—it's the core structure of our platform.” This integrated approach reflects a new standard for real-world evidence in neurology, providing invaluable insights into both neurological and behavioral health conditions that often coexist.

Clinical Data Expansion and Linkage

The expansion of NeuroBlu not only enhances patient coverage but also enriches the clinical data available for various neurological diseases. The new platform version, NeuroBlu 26R2, includes detailed data across multiple conditions:

• - Alzheimer's Disease: 520K de-identified patients
• - Mild Cognitive Impairment: 428K patients
• - Dementia: 2.1M patients
• - Parkinson's Disease: 324K patients
• - Epilepsy: 829K patients
• - Migraine: 2.7M patients
• - Sleep Disorders: 2.1M patients
• - Pain Disorders: 23.9M patients

Additionally, the platform is designed to be linkage-ready through the DataVant ecosystem, enabling life sciences organizations to access a broader view of the patient journey by connecting with claims datasets.

In-Depth Biomarker Data

For Alzheimer’s research, where stratification by amyloid and tau burden is crucial for trial designs, NeuroBlu 26R2 offers structured biomarker laboratory data. This includes over 4,600 instances of a prevalent tau biomarker assay and more than 32,000 biomarker-linked records encompassing both amyloid and tau measurements, creating a well-supported cohort for research into disease progression and treatment responses.

Holmusk also emphasizes its validated outcome measures, which shift focus from mere patient counts to a more nuanced research-grade signal. These measures cover various cognitive and behavioral health assessments that provide intricate details to researchers. For instance, they include:

• - Cognitive assessments via MoCA, MMSE, and Mini-Cog,
• - Migraine disability evaluations through MIDAS,
• - Sleep assessments via the Epworth Sleepiness Scale,
• - Motor function assessments for Parkinson's and ALS patients.

Behavioral Health Comorbidity Observability

A significant aspect of this expansion is NeuroBlu's ability to encompass a complete range of mental health diagnostics alongside neurological conditions. Approximately 19 million de-identified patients, or 41% of the platform, are documented with both neurological and behavioral health diagnoses. This holistic approach ensures accuracy in clinical observations, supporting research that benefits patients dealing with complexities arising from comorbid conditions like Alzheimer’s, Parkinson’s, and migraines.

Advanced Neuroimaging and Future Directions

NeuroBlu 26R2 has introduced structured neuroimaging encounter data, capturing various modalities and contextual information about MRI and PET scans. This data will be further enhanced with clinical interpretations and results notes expected later in 2026, allowing for thorough analyses of disease progression and treatment efficacy.

As Holmusk looks towards the future, they encourage organizations with specific data needs to engage early, ensuring that NeuroBlu continues to adapt and provide the essential data insights that support life sciences, biopharma, and biotech endeavors. For more information, interested parties can reach out through their official website at holmusk.com.

Holmusk is paving the way for enhanced research capabilities in neurology and behavioral health, marking a substantial leap in how patient data can be utilized to create effective care strategies and innovations in treatment.